Novartis India Ltd (NOVARTIND)
₹1,639.60
Mkt cap
₹4,066 Cr
P/E ratio
41.60
P/B
4.95
Div yield
1.52%
ROE
11.60%
ROCE
16.30%
EPS (TTM)
₹39.41
Book value
₹331
52W range
557–1,702
Sector
Healthcare
Price history
Previous close
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]
NSE NOVARTINDBSE 500672
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthLow
TechnicalsBullish
52-week range
−3.66% from high₹1,640
₹557+194.52% from low₹1,702
Current
₹1,639.60
Prev close
₹1,646.70
Day
−0.43%
Price performance
1D
−0.10%
1W
+5.83%
1M
+2.20%
3M
+23.55%
6M
+119.74%
1Y
+180.07%
YTD
+64.71%
Financials
Revenue, profit & margin
P/E ratio
41.6×
NOVARTIND is 22% above the sector median of 34.0×
NOVARTIND41.6×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 | |
| Expenses | 73 | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 | |
| Operating Profit | 17 | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 | |
| OPM % | 19% | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% | |
| Other Income | 12 | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Depreciation | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |
| Profit before tax | 28 | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 | |
| Tax % | 27% | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% | |
| Net Profit | 20 | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 | |
| EPS in Rs | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jul 202670.68%Promoter
Promoters70.68%
FIIs0.15%0.01
DIIs1.39%0.04
Public27.79%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| NOVARTIND | ₹1,646.70 | 41.59 | 4,066 | 1.52% | 32 | +16.62% | 104 | +18.57% | 16.26% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper Publication made on September 03, 2026, in Financial Express and Navshakti for the Intimation sent to the shareholders on September 02, 2026, regarding the …Notice Of The 78Th Annual General Meeting Of Novartis India Limited To Be Held On Thursday, September 24, 2026, Through Video Conferencing (VC) / Other Audio Visual Means (OAVM) 2 Sep - Novartis India issued FY2025-26 annual report and AGM notice for September 24, 2026; proposes ESOP 2026 and director appointments.Reg. 34 (1) Annual Report. 2 Sep - Submitted FY26 annual report and notice for 78th AGM on September 24, 2026; e-voting September 21-23.Business Responsibility and Sustainability Reporting (BRSR) 2 Sep - Novartis India filed FY2025-26 BRSR with ESG disclosures and compliance details.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 Aug - The Intimation is submitted with BSE regarding the information provided to the Members of the Company for the 78th Annual General Meeting through Newspaper Advertisement